Full access to Entrepreneur for $5
Subscribe

Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?

Sector ETF report for PSCH

By
This story originally appeared on Zacks

Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the Invesco S&P SmallCap Health Care ETF (PSCH) is a passively managed exchange traded fund launched on 04/07/2010.

- Zacks

Passively managed ETFs are becoming increasingly popular with institutional as well as retail investors due to their low cost, transparency, flexibility and tax efficiency. They are excellent vehicles for long term investors.

Sector ETFs are also funds of convenience, offering many ways to gain low risk and diversified exposure to a broad group of companies in particular sectors. Healthcare - Broad is one of the 16 broad Zacks sectors within the Zacks Industry classification. It is currently ranked 16, placing it in bottom 0%.

Index Details

The fund is sponsored by Invesco. It has amassed assets over $516.30 million, making it one of the average sized ETFs attempting to match the performance of the Healthcare - Broad segment of the equity market. PSCH seeks to match the performance of the S&P SmallCap 600 Capped Health Care Index before fees and expenses.

This Index is comprised of common stocks of U.S. healthcare companies.These are companies that are principally engaged in the business of providing healthcare-related products & services, including biotechnology, pharmaceuticals, medical technology and supplies & facilities and this Index is a subset of the S&P SmallCap 600 Index.

Costs

Investors should also pay attention to an ETF's expense ratio. Lower cost products will produce better results than those with a higher cost, assuming all other metrics remain the same.

Annual operating expenses for this ETF are 0.29%, making it one of the least expensive products in the space.

Sector Exposure and Top Holdings

Even though ETFs offer diversified exposure which minimizes single stock risk, it is still important to look into a fund's holdings before investing. Luckily, most ETFs are very transparent products that disclose their holdings on a daily basis.

This ETF has heaviest allocation in the Healthcare sector--about 100% of the portfolio.

Looking at individual holdings, Omnicell Inc (OMCL) accounts for about 5.22% of total assets, followed by Neogenomics Inc (NEO) and Amn Healthcare Services Inc (AMN).

The top 10 holdings account for about 34.08% of total assets under management.

Performance and Risk

The ETF has gained about 11.01% and was up about 47.05% so far this year and in the past one year (as of 09/09/2021), respectively. PSCH has traded between $124.15 and $198.17 during this last 52-week period.

The ETF has a beta of 1.13 and standard deviation of 28.45% for the trailing three-year period, making it a high risk choice in the space. With about 76 holdings, it effectively diversifies company-specific risk.

Alternatives

Invesco S&P SmallCap Health Care ETF carries a Zacks ETF Rank of 3 (Hold), which is based on expected asset class return, expense ratio, and momentum, among other factors. Thus, PSCH is a good option for those seeking exposure to the Health Care ETFs area of the market. Investors might also want to consider some other ETF options in the space.

Vanguard Health Care ETF (VHT) tracks MSCI US Investable Market Health Care 25/50 Index and the Health Care Select Sector SPDR ETF (XLV) tracks Health Care Select Sector Index. Vanguard Health Care ETF has $16.69 billion in assets, Health Care Select Sector SPDR ETF has $33.84 billion. VHT has an expense ratio of 0.10% and XLV charges 0.12%.

Bottom Line

To learn more about this product and other ETFs, screen for products that match your investment objectives and read articles on latest developments in the ETF investing universe, please visit Zacks ETF Center.



Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $2.4 trillion by 2028 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Recommendations from previous editions of this report have produced gains of +205%, +258% and +477%. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

 

Invesco S&P SmallCap Health Care ETF (PSCH): ETF Research Reports

 

Omnicell, Inc. (OMCL): Free Stock Analysis Report

 

AMN Healthcare Services Inc (AMN): Free Stock Analysis Report

 

NeoGenomics, Inc. (NEO): Free Stock Analysis Report

 

Health Care Select Sector SPDR ETF (XLV): ETF Research Reports

 

Vanguard Health Care ETF (VHT): ETF Research Reports

 

To read this article on Zacks.com click here.

 

Zacks Investment Research